Calendar Companies Compare Analytics Learn Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar tracking FDA decisions, clinical trial results, and PDUFA dates for biotech stocks.

Quick Links

Catalyst Calendar
Search Companies
Biotech Glossary
Therapeutic Areas

Legal

About
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

© 2025 CatalystAlert. All rights reserved.

Not financial advice. Data may be delayed or incomplete.

Efruxifermin - Phase 2 | AKRO Pipeline | CatalystAlert

Efruxifermin

Phase 2

Akero Therapeutics, Inc. (AKRO)

21%

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

Apr 2026~

AKRO⭐Phase 3Phase 2

Efruxifermin Phase 3 Results Expected

Efruxifermin • NASH - Nonalcoholic Steatohepatitis

Drug Information

Target Indication

NASH - Nonalcoholic Steatohepatitis

Clinical Trial

Last updated: 12/4/2025

Developer

AKRO

Akero Therapeutics, Inc.

Biotechnology•North America•NASDAQ